18
Mar
2016

Valeant Falls on its Sword, Carl June’s Curious Omission, & Witty’s Swan Song

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
 

You may also like

AbbVie Buys Cerevel, Roche Buys Carmot, & Crowley Steps Into the Lion’s Den
ImmunoGen’s Payday, FDA Jolts CAR-T Field, & Another Dupixent Win
UK Clears 1st CRISPR Drug, Lilly’s siRNA for CV Disease & Blackstone’s Anti-Clotting Win
Obesity Drug Rivalry Intensifies, Takeda’s Big FDA Week, & Vor Takes on AML